| Integrative analysis reveals selective 9p24. 1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and … MR Green, S Monti, SJ Rodig, P Juszczynski, T Currie, E O'Donnell, ... Blood, The Journal of the American Society of Hematology 116 (17), 3268-3277, 2010 | 1413 | 2010 |
| Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy MR Green, S Rodig, P Juszczynski, J Ouyang, P Sinha, E O'Donnell, ... Clinical cancer research 18 (6), 1611-1618, 2012 | 751 | 2012 |
| SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma L Chen, S Monti, P Juszczynski, J Daley, W Chen, TE Witzig, ... Blood, The Journal of the American Society of Hematology 111 (4), 2230-2237, 2008 | 429 | 2008 |
| The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma P Juszczynski, J Ouyang, S Monti, SJ Rodig, K Takeyama, J Abramson, ... Proceedings of the National Academy of Sciences 104 (32), 13134-13139, 2007 | 393 | 2007 |
| SYK inhibition modulates distinct PI3K/AKT-dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas L Chen, S Monti, P Juszczynski, J Ouyang, B Chapuy, D Neuberg, ... Cancer cell 23 (6), 826-838, 2013 | 210 | 2013 |
| BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltrate P Juszczynski, JL Kutok, C Li, J Mitra, RCT Aguiar, MA Shipp Molecular and cellular biology, 2006 | 185 | 2006 |
| BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms S Parekh, JM Polo, R Shaknovich, P Juszczynski, P Lev, SM Ranuncolo, ... Blood, The Journal of the American Society of Hematology 110 (6), 2067-2074, 2007 | 174 | 2007 |
| Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas JM Polo, P Juszczynski, S Monti, L Cerchietti, K Ye, JM Greally, M Shipp, ... Proceedings of the National Academy of Sciences 104 (9), 3207-3212, 2007 | 174 | 2007 |
| BBAP monoubiquitylates histone H4 at lysine 91 and selectively modulates the DNA damage response Q Yan, S Dutt, R Xu, K Graves, P Juszczynski, JP Manis, MA Shipp Molecular cell 36 (1), 110-120, 2009 | 172 | 2009 |
| Protein tyrosine phosphatase receptor–type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell–receptor signaling, and cellular proliferation L Chen, P Juszczynski, K Takeyama, RCT Aguiar, MA Shipp Blood 108 (10), 3428-3433, 2006 | 138 | 2006 |
| Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome P Juszczynski, E Kalinka, J Bienvenu, G Woszczek, M Borowiec, T Robak, ... Blood, The Journal of the American Society of Hematology 100 (8), 3037-3040, 2002 | 124 | 2002 |
| FOXO1 transcription factor: a critical effector of the PI3K-AKT axis in B-cell development M Szydłowski, E Jabłońska, P Juszczyński International reviews of immunology 33 (2), 146-157, 2014 | 89 | 2014 |
| Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders J Ouyang, P Juszczynski, SJ Rodig, MR Green, E O'Donnell, T Currie, ... Blood, The Journal of the American Society of Hematology 117 (16), 4315-4322, 2011 | 85 | 2011 |
| AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features SJ Rodig, J Ouyang, P Juszczynski, T Currie, K Law, DS Neuberg, ... Clinical Cancer Research 14 (11), 3338-3344, 2008 | 84 | 2008 |
| FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas M Szydlowski, P Kiliszek, T Sewastianik, E Jablonska, E Bialopiotrowicz, ... Blood, The Journal of the American Society of Hematology 127 (6), 739-748, 2016 | 72 | 2016 |
| MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications T Sewastianik, M Prochorec-Sobieszek, B Chapuy, P Juszczyński Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1846 (2), 457-467, 2014 | 72 | 2014 |
| Rebelled epigenome: histone H3S10 phosphorylation and H3S10 kinases in cancer biology and therapy D Komar, P Juszczynski Clinical Epigenetics 12, 1-14, 2020 | 71 | 2020 |
| BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt P Juszczynski, L Chen, E O'Donnell, JM Polo, SM Ranuncolo, ... Blood, The Journal of the American Society of Hematology 114 (26), 5315-5321, 2009 | 69 | 2009 |
| Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma M Szydłowski, M Prochorec-Sobieszek, A Szumera-Ciećkiewicz, ... Blood, The Journal of the American Society of Hematology 130 (12), 1418-1429, 2017 | 55 | 2017 |
| MLL-Rearranged B Lymphoblastic Leukemias Selectively Express the Immunoregulatory Carbohydrate-Binding Protein Galectin-1 P Juszczynski, SJ Rodig, J Ouyang, E O'Donnell, K Takeyama, ... Clinical Cancer Research 16 (7), 2122-2130, 2010 | 50 | 2010 |
